UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of
Report (Date of earliest event reported):
November 10, 2006
PEREGRINE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
0-17085
|
|
95-3698422
|
|
(State
of other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
14272
Franklin Avenue, Tustin, California 92780
|
||||
|
(Address
of Principal Executive Offices)
|
||||
|
|
|
|
|
|
|
Registrant’s
telephone number, including area code: (714)
508-6000
|
||||
|
|
||||
|
Not
Applicable
|
||||
|
(Former
name or former address, if changed since last
report)
|
||||
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| o | Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On
November 10, 2006, Peregrine Pharmaceuticals, Inc. (the “Company”) received net
proceeds of $1.2 million from ZLP Master Fund, Ltd., an institutional investor
(the “Investor”) upon the exercise of two warrants to purchase an aggregate
1,200,000 shares of common stock at an exercise price of $1.00 per share.
The
warrants were originally issued on November 16, 2001 in connection with a
financing transaction under a Securities Purchase Agreement completed on
the
same date. After the exercise of these warrants, the Company has outstanding
warrants to purchase up to 697,865 shares of common stock with a weighted
average exercise price of $1.64 per share and approximately 195,120,000 shares
of common stock outstanding.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PEREGRINE
PHARMACEUTICALS, INC.
|
||
| |
|
|
| Date: November 14, 2006 | By: | /s/ Steven W. King |
| Steven W. King | ||
| President and Chief Executive Officer, Director | ||